MedTrace Logo

Protocols for Prevention of PPH During CS in High Risk Group

NCT05099575 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 448

Last updated 2021-10-29

No results posted yet for this study

Summary

PPH is one of the most leading causes of maternal mortality,. It means loss of 500 ml blood after vaginal delivery and 1000 ml blood after cesarean delivery. Although it's preventable it represents about 27%of maternal deaths. Atony is the main cause of PPH. 70%of PPH corresponds to uterine atony. Uterotonics like oxytocin, misoprostol, ergometrine, carbetocin and combinations of these drugs can be used but until now there is no agreement on medication that can be the most effective.

Conditions

  • Atonic PPH

Interventions

DRUG

Syntocinon, papal, misotac

Using different drugs to prevent atonic PPH during CD in high risk group

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
19 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-30
Primary Completion
2022-10-30
Completion
2022-10-30
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05099575 on ClinicalTrials.gov